glp-1 discontinuation weight regain Drugs: Bridging Satiety, Nutrition, and Innovation – Kerry Health And Nutrition Institute Fractyl Health Reports Positive One-Year
Description
Semaglutide, in particular, has demonstrated a reduction in major cardiovascular events in clinical trials
The $150 billion metabolic health opportunity will belong to companies that can combine science, scale, access, and evidence
McDonnell, T., Cussen, L., McIlroy, M
DPP-IV is an enzyme responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)
doi: 10.3389/fnmol.2021.750726 Received 31 July 2021 Accepted 26 November 2021 Published 23 December 2021 Volume 14 - 2021 Edited by Yi Yang, The First Hospital of Jilin University, China Reviewed by Wei Chen, Gan & Lee Pharmaceuticals, China
Patients using non-GLP-1 options may need blood pressure checks, symptom review, or a different plan
